Use of Esketamine Nasal Spray in Patients with Treatment‐Resistant Depression in Routine Practice: A Real‐World French Study
Depression and Anxiety · 2024
DOI: 10.1155/2024/7262794 ↗Kurz gefasst
Fachartikel in der Zeitschrift Depression and Anxiety, 2024. Verfasst von Ludovic Samalin und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Clermont-Ferrand University Hospital, University of Clermont Auvergne, CNRS, IP, UMR 6602, Clermont-Ferrand, France. Hauptthemen laut MEDLINE: Depressive Disorder, Treatment-Resistant, Ketamine, Antidepressive Agents. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Depression
Abstract (Originalsprache)
Background
The efficacy and safety of esketamine nasal spray (ESK) were established in registration trials in patients with treatment‐resistant depression (TRD). This French real‐world study aimed to describe the treatment patterns, effectiveness, and safety of ESK in TRD patients over a 12‐month follow‐up. Materials and Methods . This study used secondary data from patient files of hospital‐based psychiatrists and started during the first French patient early access to ESK. The response and remission rates with ESK were analyzed using the total score of the Montgomery–Åsberg Depression Rating Scale (MADRS). The time to first treatment response and work resumption were described (Kaplan–Meier method). Adverse events (AEs) were analyzed.
Results
Prior to ESK initiation, the 157 analyzed patients (age ≤ 65 years, 82.8%; female, 66.2%) had depression for 10.5 years (median, IQR, 4.2–21.2) and received a median of 6 (3–8) previous treatment lines. At ESK initiation, the mean ± SD total MADRS score was 32.1 ± 7.7. At that time, ESK was combined with antidepressants (93.6% of patients; SNRI, 65.0%; SSRI, 57.3%) and/or other potentiation strategy (63.1%; atypical antipsychotics, 36.3%; lithium, 25.6%; antiepileptics, 21.7%). During the 12‐month follow‐up, 125 patients (79.6%) discontinued ESK. The median duration of ESK treatment was 19.4 weeks (IQR, 4.4–40.1). At 1 month after ESK initiation, 40.2% of still treated patients met criteria for clinical response and 19.7% for remission (median time to response, 5.7 weeks; 95% CI (4.1–8.4)). 82.6% of active patients were on sick leave at ESK initiation; the work resumption rate was 24% (13%–40%) 12 weeks later. AEs were reported in 68.6% of patients, serious AEs in 17.2%, and AEs leading to ESK discontinuation in 14.6%.
Conclusion
These real‐world effectiveness and safety data were consistent with findings from previous clinical trials, describing the real‐life clinical experience of patients receiving ESK and confirming that ESK has its place in therapy for the treatment of TRD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Psychiatry, Clermont-Ferrand University Hospital, University of Clermont Auvergne, CNRS, IP, UMR 6602, Clermont-Ferrand, France.
- CMME, GHU paris psychiatrie et Neurosciences, Sainte Anne Hospital, Paris, France.
- University Department of Psychiatry, Therapeutic Excellence Center, Psychiatry Institute, Rouvray Hospital, Sotteville-lès-Rouen, France.
- Nantes University, Nantes University Hospital, Movement-Interactions-Performance, Nantes, France.
- Medical Affairs, Janssen-Cilag, Issy-les-Moulineaux, France.
ORCID-Profile: Ludovic Samalin, Lila Mekaoui, Maud Rothärmel, Anne Sauvaget, Clotilde Wicart, Julien Dupin, Vanessa Cohignac, Emeline Gaudre-Wattinne
Zitieren
APA
Samalin, L., Mekaoui, L., Rothärmel, M., Sauvaget, A., Wicart, C., Dupin, J., Cohignac, V., & Gaudre-Wattinne, E. (2024). Use of Esketamine Nasal Spray in Patients with Treatment‐Resistant Depression in Routine Practice: A Real‐World French Study. Depression and Anxiety. https://doi.org/10.1155/2024/7262794
Vancouver
Samalin L, Mekaoui L, Rothärmel M, Sauvaget A, Wicart C, Dupin J, et al. Use of Esketamine Nasal Spray in Patients with Treatment‐Resistant Depression in Routine Practice: A Real‐World French Study. Depression and Anxiety. 2024. doi:10.1155/2024/7262794
BibTeX
@article{Samalin2024,
author = {Samalin, Ludovic and Mekaoui, Lila and Rothärmel, Maud and Sauvaget, Anne and Wicart, Clotilde and Dupin, Julien and Cohignac, Vanessa and Gaudre-Wattinne, Emeline},
title = {Use of Esketamine Nasal Spray in Patients with Treatment‐Resistant Depression in Routine Practice: A Real‐World French Study},
journal = {Depression and Anxiety},
year = {2024},
doi = {10.1155/2024/7262794}
}
EUVIMED